Tags: Amyvid™

blog

PET Scans Improve Management of Patients with Dementia

A national study has found that PET scans significantly influenced clinical management of patients with dementia.

blog

Top Five Highlights from AAIC 2018

The ADDF looks back at the 2018 Alzheimer's Association International Conference.

blog

Alzheimer’s Biomarkers, Explained

Learn what a biomarker is, why they matter to the ADDF, which biomarkers we have, and which ones we need.  

blog

Prevention: A Key to Conquering Alzheimer's

Dr. Howard Fillit explains the importance of prevention to the ADDF's mission and our current efforts, including clinical trials. 

blog

What Does the Failure of Solanezumab Mean?

Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means, and where we go from here.

blog

ADDF-Funded PET Imaging Makes Clinical Trial Success Possible

A treatment has reduced beta-amyloid plaques in the brains of patients with Alzheimer’s disease. 

blog

Alzheimer’s Drug Featured in Time Was Made Possible by the ADDF

Grantee Dr. Frank Longo's promising new drug to treat Alzheimer's is on the cover of Time magazine.

blog

Investing in a Cure

Investing more in drug discovery and development is the best chance we have for finding a cure for Alzheimer's disease.

blog

The Balancing Act of Healthcare Reform

I recently saw a patient who was afraid he had Alzheimer's disease. A new scan made it easy to give him an accurate diagnosis. So why can't most patients use it? 

blog

Fighting Alzheimer’s Costs Now & in the Future

The current costs of dementia care are enormous. But the future costs could create a crippling financial burden on our society, as the number of people diagnosed with dementia is expected to more than double in the next 30 years.